SCHEMBL2998094

SCHEMBL2998094

COc1cc(OC)cc(-c2csc(N3CCC(S(=O)(=O)c4ccccc4Cl)CC3)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.50
ALDH1A1 P00352 6/20 0.49
LMNA P02545 6/20 0.49
MAPK1 P28482 5/20 0.49
RAB9A P51151 5/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
HSD17B10 Q99714 3/20 0.48
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HTT P42858 1/20 0.47
HPGD P15428 1/20 0.47
NPC1 O15118 3/20 0.46
KCNQ1 P51787 1/20 0.45
FAAH O00519 1/20 0.44
EPHX2 P34913 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006240 0.93 MAPT (0.49) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3018528 0.93 MAPT (0.59) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3001759 0.91 MAPT (0.61) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3016467 0.90 MAPT (0.47) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3015770 0.90 RAB9A (0.46) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3013711 0.89 MAPK1 (0.54) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3018794 0.89 MAPT (0.50) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3014009 0.88 SMN1; SMN2 (0.53) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3016485 0.88 RAB9A (0.45) MAPTALDH1A1LMNAMAPK1RAB9A
SCHEMBL3005397 0.88 MAPT (0.52) MAPTALDH1A1LMNAMAPK1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.